ClinicalTrials.Veeva

Menu

A Convolutional Neural Network for Difficult Biliary Cannulation (PRECABIDO2)

U

University of La Laguna

Status

Not yet enrolling

Conditions

Difficult Biliary Cannulation

Treatments

Procedure: Endoscopic retrograde cholangiopancreatography (ERCP)

Study type

Observational

Funder types

Other

Identifiers

NCT07389915
CNN difficult cannulation

Details and patient eligibility

About

The main purpose of the study is to train a convolutional neural network (CNN) to predict difficult biliary canulation (DBC) following the European Society of Gastrointestinal Endoscopy Society (ESGE). Consecutive patients undergoing an endoscopic retrograde cholangiopancreatography (ERCP) will be included in the study. Several pictures of the second portion of the duodenum including the ampulla will be taken, along with several pictures of the radiological image. Pictures prospectively collected from the study PRECABIDO (NCT06591364), a multicenter study whith the purpose of evaluating the prevalence of difficult biliary cannulation and predictive factors for difficult cannulation and cannulation failure using ESGE criteria were also used for the training of the CNN.

We will also assess:

A validation of the CNN assessing the agreement between ESGE criteria and the CNN prediction.

To design a novel application based on the use of a convolutional neural network (CNN) to detect difficult biliary cannulation.

.

Full description

All consecutive patients who meet the inclusion criteria and none of the exclusion criteria will be offered participation in the study. They will be informed by one of the investigators from each center and will sign an informed consent form. A data collection sheet will be completed to record demographic data, the indication for the procedure, and technical variables.

The procedures will be performed by endoscopists with at least 200 ERCPs and more than 5 years of experience. All patients, except in cases of allergy, will receive 1 suppository of indomethacin or diclofenac before the procedure. In cases of allergy, pre-procedure hydration with Ringer's lactate will be administered if there is no contraindication (consider the protocol proposed by the ESGE: 3 mL/kg/hour during ERCP, 20 mL/kg as a bolus after ERCP, and 3 mL/kg/hour for 8 hours post-ERCP). The use of a pancreatic stent should be considered when indicated.

After the procedure, patients will remain hospitalized for at least 24 hours in the hospital. The patient's medical record will be reviewed 7 days after the procedure to check for any adverse effects, and a follow-up phone call will be made to detect any adverse effects.

Initially, a pilot study will be conducted with 600 patients, assessing based on the results-that is, the percentage of patients with difficult cannulation. At the beginning of the examination, at least three endoscopic images and three radiological images of the second portion of the duodenum will be captured for each patient. In patients undergoing endoscopic ultrasound (EUS), three additional images of the second portion of the duodenum at the level of the pancreatic head and common bile duct (CBD) will be obtained.

These images will be labeled as "CBD yes" or "CBD no" according to ESGE criteria, which will serve as the gold standard. Once labeled, the images will be used to train a convolutional neural network (CNN) capable of predicting, just before attempting biliary cannulation, whether it will be a CBD or not.

The prediction of the trained CNN will be able to be combined with the predictive model of difficult biliary cannulation obtaned from the study PRECABIDO NCT06591364 in order to improve the prediction.

Enrollment

600 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age >18 years
  • Signed informed consent
  • Patients indicated for ERCP

Exclusion criteria

  • INR > 1.5
  • Platelets < 50,000/mm³
  • Patients with a prior endoscopic sphincterotomy
  • Papilla of Vater not accessible via duodenoscope (gastric or duodenal stenosis due to neoplasm) or gastric surgery (Billroth II, Roux-en-Y)
  • Known pancreas divisum
  • Indication due to pancreatic duct pathology

Trial design

600 participants in 1 patient group

Patients undergoing ERCP
Description:
Consecutive patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) will be included
Treatment:
Procedure: Endoscopic retrograde cholangiopancreatography (ERCP)

Trial contacts and locations

0

Loading...

Central trial contact

Antonio Z Gimeno García, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems